Insmed Company Leadership
INSM Stock | USD 73.81 1.14 1.57% |
Insmed's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Insmed Inc suggests that most insiders are panicking. Insmed employs about 912 people. The company is managed by 16 executives with a total tenure of roughly 14 years, averaging almost 0.0 years of service per executive, having 57.0 employees per reported executive.
Insmed's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-09-16 | Martina M.D. Flammer | Disposed 13436 @ 74.92 | View | ||
2024-09-13 | Michael Alexander Smith | Disposed 27871 @ 74.35 | View | ||
2024-09-10 | Orlov S Nicole Schaeffer | Disposed 37575 @ 71.5 | View | ||
2024-06-21 | Josh Gottheimer | Disposed @ 67.99 | |||
2024-05-30 | Martina M.D. Flammer | Disposed 21195 @ 55 | View | ||
2024-05-29 | Sara Bonstein | Disposed 220564 @ 50 | View | ||
2024-05-28 | Josh Gottheimer | Disposed @ 48.06 | |||
2024-05-14 | Sara Bonstein | Disposed 11088 @ 25.32 | View | ||
2024-01-12 | Martina M.D. Flammer | Disposed 4667 @ 28.63 | View | ||
2024-01-09 | Sara Bonstein | Disposed 4497 @ 29.18 | View | ||
2024-01-08 | William Lewis | Disposed 45120 @ 29.45 | View | ||
2024-01-05 | John Drayton Wise | Disposed 1167 @ 29.32 | View |
Monitoring Insmed's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Insmed |
Insmed's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Insmed's future performance. Based on our forecasts, it is anticipated that Insmed will maintain a workforce of about 910 employees by December 2024.Insmed's latest congressional trading
Congressional trading in companies like Insmed Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Insmed by those in governmental positions are based on the same information available to the general public.
2024-07-09 | Representative Josh Gottheimer | Acquired Under $15K | Verify | ||
2024-06-08 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Insmed Management Team Effectiveness
The company has return on total asset (ROA) of (0.2605) % which means that it has lost $0.2605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9075) %, meaning that it created substantial loss on money invested by shareholders. Insmed's management efficiency ratios could be used to measure how well Insmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Equity is likely to grow to 2.37, while Return On Tangible Assets are likely to drop (0.70). At this time, Insmed's Intangibles To Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Debt To Assets is likely to grow to 0.91, though Net Tangible Assets are likely to grow to (127.7 M).As of the 22nd of November 2024, Common Stock Shares Outstanding is likely to grow to about 147.5 M, though Net Loss is likely to grow to (411.7 M).
Insmed Workforce Comparison
Insmed Inc is rated third overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 18,019. Insmed holds roughly 912 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.52) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.13. Insmed Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insmed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insmed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Insmed insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 0.5357 | 15 | 28 | 332,687 | 685,809 |
2024-06-01 | 1.0698 | 46 | 43 | 1,372,316 | 1,116,822 |
2024-03-01 | 1.0 | 24 | 24 | 885,105 | 149,560 |
2023-12-01 | 0.6923 | 9 | 13 | 163,098 | 338,395 |
2023-06-01 | 1.3478 | 31 | 23 | 2,108,115 | 66,347 |
2023-03-01 | 1.1429 | 16 | 14 | 377,634 | 40,086 |
2022-12-01 | 1.5 | 3 | 2 | 75,000 | 19,009 |
2022-09-01 | 0.4167 | 5 | 12 | 313,414 | 755,271 |
2022-06-01 | 2.625 | 21 | 8 | 1,178,573 | 15,964 |
2022-03-01 | 0.7619 | 16 | 21 | 649,230 | 195,016 |
2021-12-01 | 0.4545 | 5 | 11 | 135,235 | 317,128 |
2021-09-01 | 0.6667 | 4 | 6 | 153,235 | 227,926 |
2021-06-01 | 4.6 | 23 | 5 | 647,706 | 14,965 |
2021-03-01 | 0.6889 | 31 | 45 | 636,656 | 750,971 |
2020-12-01 | 0.6066 | 37 | 61 | 1,503,154 | 1,723,887 |
2020-09-01 | 0.3636 | 4 | 11 | 60,272 | 140,544 |
2020-06-01 | 2.2 | 11 | 5 | 109,368 | 11,746 |
2020-03-01 | 3.2 | 16 | 5 | 1,147,742 | 31,152 |
2019-12-01 | 4.0 | 4 | 1 | 80,158 | 25,000 |
2019-06-01 | 2.2857 | 16 | 7 | 748,712 | 714,256 |
2019-03-01 | 0.8 | 8 | 10 | 1,375,100 | 64,699 |
2018-06-01 | 1.5 | 9 | 6 | 80,037 | 87,360 |
2018-03-01 | 12.0 | 12 | 1 | 604,786 | 15,080 |
2017-12-01 | 0.5 | 1 | 2 | 15,000 | 30,000 |
2017-09-01 | 0.1 | 1 | 10 | 15,000 | 125,000 |
2017-06-01 | 17.0 | 17 | 1 | 650,410 | 17,080 |
2017-03-01 | 1.75 | 7 | 4 | 435,910 | 61,500 |
2016-12-01 | 0.8182 | 9 | 11 | 226,834 | 181,514 |
2016-06-01 | 11.0 | 11 | 1 | 623,002 | 37,500 |
2016-03-01 | 6.0 | 6 | 1 | 413,000 | 12,500 |
2015-12-01 | 1.0 | 1 | 1 | 244.00 | 244.00 |
2015-06-01 | 1.8 | 9 | 5 | 345,432 | 52,534 |
2015-03-01 | 7.3333 | 22 | 3 | 382,110 | 5,250 |
2014-12-01 | 2.0 | 2 | 1 | 946.00 | 702.00 |
2014-06-01 | 1.1 | 11 | 10 | 250,440 | 267,750 |
2014-03-01 | 2.4286 | 17 | 7 | 247,743 | 83,068 |
2013-12-01 | 4.0 | 4 | 1 | 264,890 | 8,955 |
2013-09-01 | 0.1379 | 4 | 29 | 161,912 | 1,147,221 |
2013-06-01 | 0.6471 | 11 | 17 | 787,716 | 492,696 |
2013-03-01 | 3.0 | 15 | 5 | 321,184 | 56,684 |
2012-12-01 | 1.0 | 1 | 1 | 13,568 | 175,000 |
2012-09-01 | 2.0 | 2 | 1 | 894,484 | 4,327 |
2012-03-01 | 2.0 | 10 | 5 | 87,154 | 30,470 |
2011-03-01 | 28.0 | 28 | 1 | 22,716,056 | 54,688 |
2009-03-01 | 1.3846 | 18 | 13 | 2,721,131 | 2,975,044 |
2008-12-01 | 0.5 | 1 | 2 | 100,000 | 50,000 |
2007-06-01 | 15.0 | 15 | 1 | 385,800 | 250,000 |
2005-12-01 | 0.2222 | 2 | 9 | 250,000 | 501,163 |
2005-03-01 | 1.0 | 2 | 2 | 93,500 | 93,500 |
2004-12-01 | 0.6667 | 2 | 3 | 5,000 | 0.00 |
2004-06-01 | 2.0 | 4 | 2 | 70,000 | 200,000 |
2003-12-01 | 0.125 | 2 | 16 | 7,183 | 59,543 |
2003-09-01 | 0.1429 | 1 | 7 | 8,125 | 21,187 |
Insmed Notable Stakeholders
An Insmed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Insmed often face trade-offs trying to please all of them. Insmed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Insmed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MBA JD | CEO President | Profile | |
Nicole Schaeffer | Sr. VP of HR and Corporate Services | Profile | |
Mandy Fahey | Executive Communications | Profile | |
Sara MBA | Chief Officer | Profile | |
Nicole MBA | Chief Officer | Profile | |
John Wise | Head VP | Profile | |
Eleanor Barisser | Associate Relations | Profile | |
MD MBA | Chief Officer | Profile | |
Roger Adsett | Chief Commercial Officer | Profile | |
John III | VP Officer | Profile | |
John MBA | Chief Officer | Profile | |
Michael Smith | Sr Counsel | Profile | |
Michael JD | Chief Secretary | Profile | |
Roger MBA | Chief Officer | Profile | |
Brian Kaspar | Chief Officer | Profile | |
MD FCCP | Chief Officer | Profile |
About Insmed Management Performance
The success or failure of an entity such as Insmed Inc often depends on how effective the management is. Insmed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Insmed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Insmed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.66) | (0.70) | |
Return On Capital Employed | (0.64) | (0.61) | |
Return On Assets | (0.56) | (0.59) | |
Return On Equity | 2.26 | 2.37 |
Insmed Workforce Analysis
Traditionally, organizations such as Insmed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Insmed within its industry.Insmed Manpower Efficiency
Return on Insmed Manpower
Revenue Per Employee | 334.7K | |
Revenue Per Executive | 19.1M | |
Net Loss Per Employee | 821.9K | |
Net Loss Per Executive | 46.8M | |
Working Capital Per Employee | 771.3K | |
Working Capital Per Executive | 44M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.